Evidence map›Paper›PMID 37771723›Full record

ArticleFrontiers in pharmacology2023

Dipyridamole activates adenosine A2B receptor and AMPK/cAMP signaling and promotes myogenic differentiation of myoblastic C2C12 cells.

Miguel Marco-Bonilla, Raquel Herencia, María Fresnadillo, Fernando Huete-Toral, Gonzalo Carracedo, Raquel Largo, Gabriel Herrero-Beaumont, Aránzazu Mediero

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Reply.Arthritis & rheumatology (Hoboken, N.J.) · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Energy Regulation in Inflammatory Sarcopenia by the Purinergic System.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Miguel Marco-BonillaBone and Joint Research Unit, FIIS-Fundación Jiménez Díaz UAM, Madrid, Spain.
Raquel HerenciaBone and Joint Research Unit, FIIS-Fundación Jiménez Díaz UAM, Madrid, Spain.
María FresnadilloBone and Joint Research Unit, FIIS-Fundación Jiménez Díaz UAM, Madrid, Spain.
Fernando Huete-ToralOcupharm Group Research, Faculty of Optic and Optometry, University Complutense of Madrid, Madrid, Spain.
Gonzalo CarracedoOcupharm Group Research, Faculty of Optic and Optometry, University Complutense of Madrid, Madrid, Spain.
Raquel LargoBone and Joint Research Unit, FIIS-Fundación Jiménez Díaz UAM, Madrid, Spain.
Gabriel Herrero-BeaumontBone and Joint Research Unit, FIIS-Fundación Jiménez Díaz UAM, Madrid, Spain.
Aránzazu MedieroBone and Joint Research Unit, FIIS-Fundación Jiménez Díaz UAM, Madrid, Spain.
Hospital Universitario Fundación Jiménez Díaz · ESUniversidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

A2B receptoradenosinedipyridamolemusclesarcopenia

Identifiers

PMID37771723
PMCPMC10522837
OpenAlexW4386723532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.